Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,814.89
(
-0.11%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Praveen post# 32355

Sunday, 08/06/2006 2:57:23 PM

Sunday, August 06, 2006 2:57:23 PM

Post# of 257268
Hi Praveen. The Xigris article I just posted mentioned Protherics (about 3/4 of the way down):

>>
Worse still for Xigris, although the threat of Chiron/Pharmacia's tifacogin has receded, competition may soon be on its way in other forms, including ICOS/Suntory's Pafase, Abbott's afelimomab, and Protherics' CytoTAb target tumor necrosis factor.
<<

I’ll have to learn something about these programs to see if they are serious candidates in the sepsis arena. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today